Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2596
Peer-review started: July 31, 2023
First decision: September 5, 2023
Revised: September 15, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: November 27, 2023
Processing time: 118 Days and 19.6 Hours
Branched chain amino acids (BCAA) show promising results in improving surgical outcomes in liver cancer patients and potential for routine use.
Current studies on BCAA supplementation show varying results but with no clear conclusion and no updated reviews on the matter.
To provide the most updated review on whether BCAA supplementation provides measurable benefits in liver cancer patients for surgical intervention.
Current trials and studies on BCAA supplementation in liver cancer patients undergoing surgery were appraised by three independent authors. Studies were identified and data extracted for meta-analysis of the relevant outcomes.
Perioperative BCAA supplementation reduced postoperative infections, length of stay and increased body weight in the studied patient groups but did not improve mortality, oncological recurrence, and long-term survival.
This review has shown that BCAA supplementation improves postoperative outcomes with no significant side effects. However, benefits on oncological outcomes remain inconclusive.
This review highlights the possible routine use of BCAA for liver cancer patients for surgical intervention. Further clinical research can be directed at assessing optimal BCAA supplementation regime for such patients.